Document Detail


THE DETERMINANTS OF PRICING IN PHARMACEUTICALS: ARE US PRICES REALLY SO HIGH?
MedLine Citation:
PMID:  23303712     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
This paper studies price determination in pharmaceutical markets using data for 25 countries, 6 years, and a comprehensive list of products from the MIDAS IMS database. A key finding is that the USA has prices that are not significantly higher than those of countries with similar income levels, especially those that are 'lightly regulated'. More importantly, price differences to the US levels increase for 'branded', world top selling, or innovative products, and decrease, regardless of the level of regulation for mature or widely diffused molecules. Because prices for top selling molecules may be easier to perceive and recollect and more important for companies, they may bias the public discussion about international price differences. Copyright © 2013 John Wiley & Sons, Ltd.
Authors:
Antonio Cabrales; Sergi Jiménez-Martín
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-10
Journal Detail:
Title:  Health economics     Volume:  -     ISSN:  1099-1050     ISO Abbreviation:  Health Econ     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9306780     Medline TA:  Health Econ     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013 John Wiley & Sons, Ltd.
Affiliation:
Universidad Carlos III de Madrid, Economics, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Membrane Microreactors: Gas-Liquid Reactions Made Easy.
Next Document:  Proteomic methods reveal cyclophilin a functions as a host restriction factor against rotavirus infe...